Hundreds of bad reactions linked to weight loss jabs prompts new study

Research set to focus on genetic testing following reports of side effects

- 

HUNDREDS of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects.

Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal.

Data from the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.

This includes:

■ 181 reported cases of acute and chronic pancreatitis linked to tirzepatide - the active ingredient for Mounjaro. Five people died.

■ 116 reported reactions of this kind linked to liraglutide, one of which was fatal.

■ 113 cases of acute and chronic pancreatitis linked to semaglutide - the active ingredient for Ozempic and Wegovy. One person died.

■ 101 reported reactions of this kind linked to exenatide, three people died.

■ 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions to lixisenatide. No fatalities were linked to either drug.